-+ 0.00%
-+ 0.00%
-+ 0.00%

BOEHRINGER INGELHEIM: TREATMENT DISCONTINUATION RATES DUE TO GI ADVERSE EVENTS 19.3% & 20.8% IN PEOPLE WHO RECEIVED 3.6MG AND 6.0MG SURVODUTIDE DOSES RESPECTIVELY

Reuters·11/09/2026 14:45:06

Please log in to view news